Selected Publications

Berman JN, Verma A, Viola S, Alonzo TA, Wang YC, Brodersen LE, Loken M, Beckman A, Hirsch B, Raimondi S, Chisholm KM, Ma X, Ries R, Meshinchi S, Gamis A, Schore R, Taub JW, Kolb EA, Cooper T, Hitzler J: Molecular risk markers define risk of relapse in myeloid leukemia of Down syndrome beyond measurable residual disease. Blood Advances 10(5): 1576–1586, March 2026.

Zwaan CM, Tasian SK, Aplenc R, Brodersen LE, Buldini B, De Moerloose B, Dworzak MN, Fogelstrand L, Gibson BE, Goemans BF, Hasle H, Hirsch BA, Kaspers GJ, Klusmann JH, Kutny MA, Lehrnbecher T, Locatelli F, Meshinchi S, Petit A, Pigazzi M, Tierens A, Kolb EA, Reinhardt D, Tomizawa D, Cooper TM: Diagnosis and Management of AML in Pediatric Patients: Consensus Recommendations from an International Expert Panel. Blood October 2025.

Menssen AJ, Hudson CA, Alonzo T, Gerbing R, Pardo L, Leonti A, Cook JA, Hsu FC, Lott LL, Dai F, Fearing C, Ghirardelli K, Hylkema T, Tarlock K, Loeb KR, Kolb EA, Cooper T, Pollard J, Wells DA, Loken MR, Aplenc R, Meshinchi S, Eidenschink Brodersen L: CD74 is Expressed in a Subset of Pediatric Acute Myeloid Leukemia Patients and is a Promising Target for Therapy: a Report From the Children's Oncology Group. Haematologica 109(10): 3182-3193, October 2024.

Pigazzi M, Tregnano C, Hudson CA, and Eidenschink Brodersen L: Measurable Residual Disease Assessment in Pediatric AML. Tomizawa, D., Kolb, E.A., Reinhardt, D. (eds) Acute Myeloid Leukemia in Children. Springer, Page: 79-101, August 2024 Notes: https://doi.org/10.1007/978-3-031-63366-9_5.

Lambo S, Trinh DL, Ries RE, Jin D, Setiadi A, Ng M, Leblanc VG, Loken MR, Eidenschink Brodersen L, Dai F, Pardo LM, Ma X, Vercauteren SM, Meshinchi S, Marra MA: A Longitudinal Single-Cell Atlas of treatment Response in Pediatric AML. Cancer Cell 41(12): 2117-2135, December 2023.

Tarlock K, Ostronoff F, Pogosova-Agadjanyan EL, Kaspers GJL, Hasle H, Dworzak M, Walter C, Muhlegger N, Morerio C, Pardo L, Hirsch B, Raimondi S, Cooper TM, Aplenc R, Gamis AS, Kolb EA, Farrar JE, Stirewalt D, Ma X, Shaw TI, Furlan SN, Eidenschink Brodersen L, Loken MR, Van den Heuvel-Eibrink MM, Zwaan CM, Triche TJ, Goemans BF, Meshinchi S. : Comprehensive Molecular Characterization of NUP98 Fusions in Pediatric Acute Myeloid Leukemia. Haematologica 108(8): 2044-2058, August 2023.

Hsu FC, Hudson C, Wilson ER, Pardo LM, Singleton TP, Xu D, Zehentner BK, Hitzler J, Berman J, Wells DA, Loken MR, Eidenschink Brodersen L: The Impact of Down Syndrome-Specific Non-Malignant Hematopoietic Regeneration in the Bone Marrow on the Detection of Leukemic Measurable Residual Disease. Cytometry B Clin Cytom 104(4): 311-318, July 2023.

Le Q, Tang T, Leonti A, Castro S, McKay CN, Perkins L, Pardo L, Kirkey D, Hylkema T, Call L, Manselle M, Abrahams C, Bedard K, Molina A, Eidenschink Brodersen L, Loken MR, Tarlock K, Meshinchi S, Loeb KR: Preclinical Studies Targeting CD74 With STRO-001 Antibody-drug Conjugate in Acute Leukemia. Blood Advances 7(9): 1666-1670, May 2023.

Kirkey DC, Loeb AM, Castro S, McKay CN, Perkins L, Pardo L, Leonti AR, Tang TT, Loken MR, Eidenschink Brodersen L, Loeb KR, Scheinberg DA, Le Q, Meshinchi S: Therapeutic Targeting of PRAME with mTCR CAR T Cells in Acute Myeloid Leukemia. Blood Advances 7(7): 1178-1189, April 2023.

Porwit A, Béné MC, Duetz C, Matarraz S, Oelschlaegel U, Westers TM, Wagner-Ballon O, Kordasti S, Valent P, Preijers F, Alhan C, Bellos F, Bettelheim P, Burbury K, Chapuis N, Cremers E, Della Porta MG, Dunlop A, Eidenschink Brodersen L, Font P, Fontenay M, Hobo W, Ireland R, Johansson U, Loken MR, Ogata K, Orfao A, Psarra K, Saft L, Subira D, Te Marvelde J, Wells DA, van der Velden VHJ, Kern W, van de Loosdrecht AA. : Multiparameter Flow Cytometry in the Evaluation of Myelodysplasia: Analytical Issues: Recommendations From the European LeukemiaNet/International Myelodsyplastic Syndrome Flow Cytometry Working Group. Cytometry B Clin Cytom 104(1): 27-50, January 2023.